Founded in 2015, Inito makes a smartphone-connected fertility monitor that delivers quantitative hormone diagnostics at home. The device measures biomarkers such as FSH, estrogen, LH and PdG, and its AI models have interpreted more than 30 million hormone data points to date. Building on this dataset, the company is developing an expanded at-home hormone and general health diagnostics platform using AI-engineered antibodies. Revenue has grown from roughly Rs 2 crore in FY19 to Rs 67.6 crore in FY25, although year-over-year topline growth slowed to 27% in the most recent fiscal year. Total equity funding now stands at $45 million. Future plans center on broadening the menu of hormone tests that can be performed at home and deepening the AI capabilities that interpret those results.

Total raised

$35M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2025